Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | HNF4A | P41235 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330266 | 0.72 | RXRA (0.35) | RXRARARARARBRARG | |
| SCHEMBL2197626 | 0.71 | RXRA (0.36) | RXRARARARARBRARG | |
| SCHEMBL5486085 | 0.68 | RXRA (0.31) | RXRARARBRARG | |
| SCHEMBL5491284 | 0.68 | RXRA (0.35) | RXRARARARARBRARG | |
| SCHEMBL4446990 | 0.68 | RXRA (0.36) | RXRAHNF4ARARARARBRARG | |
| SCHEMBL11599145 | 0.67 | RXRA (0.42) | RXRARARARARBRARG | |
| SCHEMBL8202817 | 0.64 | RXRA (0.40) | RXRAHNF4ARARARARBRARG | |
| SCHEMBL455692 | 0.63 | — | — | |
| SCHEMBL15347722 | 0.63 | RXRA (0.60) | RXRAHNF4A | |
| SCHEMBL7583942 | 0.62 | RARG (0.32) | RXRAHNF4ARARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | claimed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | claimed |
| EP-1214305-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016123-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | PFAHL MAGNUS | 2006-07-20 | — | — | US | disclosed |
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-01-05 | — | — | US | disclosed |
| US-6974826-B2 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1593677-A2 | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes | Incyte San Diego Incorporated (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1214305-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016123-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | FABP4, HPGDS, GPR119 | RXRA 307/4885HNF4A 165/4885RARA 311/4885 |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, PC, PNLIP | RXRA 778/4885HNF4A 54/4885RARA 1231/4885 |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | RXRA 793/4885HNF4A 191/4885RARA 1352/4885 |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, GPR119, IL2 | RXRA 618/4885HNF4A 198/4885RARA 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.